Agenus Inc. (AGEN) Earnings Call Transcripts

Agenus Inc.'s Latest Earnings Call - March 31, 2026

In the first quarter of 2026, Agenus Inc. reported significant progress in its clinical development of BOT/BAL, focusing on expanding immunotherapy access for patients with microsatellite stable (MSS) colorectal cancer. The company highlighted a revenue of $3.2 million from its access programs, reflecting growing physician interest and patient demand. Management maintained a positive outlook, emphasizing the importance of 2026 for regulatory filings and operational readiness, although they acknowledged challenges in market valuation despite clinical advancements.

Reported metrics

Guidance from management

Management emphasized 2026 as a pivotal year for executing regulatory filings and expanding patient access programs, with a focus on the BATTMAN trial and potential neoadjuvant studies.

What management said

Thank you so much for that, Steven. And thank you, too, for just sharing a little bit about your history because I think it's so relevant and to share the context of what never thought was possible in melanoma and now setting the stage for hope for additional tumors as we move forward. So you talked a lot about durability. Can you maybe just share and expand upon that a little bit more about what you're seeing in te...

Thank you, Steven. So you elegantly explained that much better than I did in the opening about what makes a cold tumor cold. So essentially, as I've heard you describe before, it's this one-two punch, it's really that botensilimab is priming and amplifying right, the immune system and creating that memory and teaching it while as you explained, balstilimab really helps sustain the response, and that's why we actually...

What analysts pressed on

Analysts expressed concerns regarding the disconnect between clinical advancements and market valuation, questioning how the company plans to bridge this gap and effectively communicate its progress to investors.

Main topics on the call

• Clinical Progress of BOT/BAL — Agenus reported that over 1,200 patients have been treated with the BOT/BAL combination across nine tumor types, demonstrating 'consistent, meaningful clinical activity in tumors that have historically been resistant to ...
• Expansion of Patient Access Programs — The company has initiated both a paid named-patient program and a French AAC program, with 270 inquiries from 30 countries. Garo Armen noted, 'patients are desperate for treatments,' indicating strong demand for BOT/BAL ...
• Regulatory Pathway and BATTMAN Study — The Phase III BATTMAN trial is designed to evaluate BOT/BAL in refractory MSS colorectal cancer. Dr. O'Day stated, 'It is critical that we design and test this in a randomized Phase III setting with survival as the signa...
• Market Valuation Disconnect — Management acknowledged a disconnect between clinical progress and market valuation. Garo Armen stated, 'there is a disconnect between the progress we're making and the value the market assigns to Agenus,' indicating a n...

Read the full Agenus Inc. transcript (March 31, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 42 Agenus Inc. earnings call transcripts on record, spanning February 20, 2020 to July 13, 2026. Based on this history, Agenus Inc. reports quarterly. The most recent call on file is dated July 13, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

AGEN

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

42

First call

February 20, 2020

Most recent

July 13, 2026

Reporting cadence

quarterly